Chronic Phase Chronic Myeloid Leukemia — Patent Landscape

Aggregated US Orange Book patent estate across every approved drug for chronic phase chronic myeloid leukemia. 42 active patents protecting 1 drugs from 1+ originators. First major cliff: 2026. Daily refresh.

1
Approved drugs
42
Active US patents
61/100
Avg vulnerability
$493M
Annual revenue covered

Originators in Chronic Phase Chronic Myeloid Leukemia

Companies holding active patents on drugs approved for this indication. Click through to each company's full patent dashboard.

Handa Therap 42 patents

Cliff calendar — next 15 years

Patent expiries per year across all drugs treating chronic phase chronic myeloid leukemia. Each bar = one year. Y-axis scaled to peak year (36 patents).

6
26
36
41

Approved drugs ranked by patent estate

Drug Originator Active patents Avg vuln Revenue First cliff
Sprycel
dasatinib
 Handa Therap 42 61 $493M 2026-09-28

Most attackable patents

Highest vulnerability scores in the indication — paragraph IV / IPR / design-around candidates.

Patent Drug Type Vuln Expiry
7491725 Sprycel other 80 2026-09-28
7491725 Sprycel other 80 2026-09-28
7491725 Sprycel other 80 2026-09-28
7491725 Sprycel other 80 2026-09-28
7491725 Sprycel other 80 2026-09-28
7491725 Sprycel other 80 2026-09-28
12544376 Sprycel method of use 75 2041-01-22
12433891 Sprycel method of use 75 2041-01-22
12433891 Sprycel method of use 75 2041-01-22
12433891 Sprycel method of use 75 2041-01-22

Strongest defences

Lowest vulnerability scores — pillars of the indication's IP fortress.

Patent Drug Type Vuln Expiry
11298356 Sprycel formulation 50 2041-01-22
11298356 Sprycel formulation 50 2041-01-22
11298356 Sprycel formulation 50 2041-01-22
11298356 Sprycel formulation 50 2041-01-22
11298356 Sprycel formulation 50 2041-01-22
11298356 Sprycel formulation 50 2041-01-22
12465606 Sprycel formulation 55 2041-01-22
12465606 Sprycel formulation 55 2041-01-22
12465606 Sprycel formulation 55 2041-01-22
12465606 Sprycel formulation 55 2041-01-22

Related